Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

CYRX earnings analysis

Filed May 5, 2026 · Our reading of the company's report

The latest report

Cryoport, Inc. (CYRX) reported Q1 revenue of $47.8 million, growing 16.5% year-over-year, driven by strong performance in both Life Sciences Services and Life Sciences Products segments. Despite missing EPS expectations…

Read full summary

Cryoport, Inc. (CYRX) reported Q1 revenue of $47.8 million, growing 16.5% year-over-year, driven by strong performance in both Life Sciences Services and Life Sciences Products segments. Despite missing EPS expectations with a loss of $0.25 against an estimate of $0.19, management issued an optimistic outlook, raising full-year revenue guidance to $192 million-$196 million.

Read the original on SEC.gov

Where revenue came from

The business segments reported by the company.

Life Sciences Services 56.3% Life Sciences Products 43.7%

Shares of the segments disclosed in this filing, largest first.

Reported figures

Earnings per share
$-0.25
Gross margin
45.8%

What stood out

  • Strong Revenue Growth

    Revenue increased by 16.5%, reaching $47.8 million compared to $41.0 million in Q1 2025.

  • Segment Performance Boost

    Life Sciences Services revenue grew 17.6% to $26.9 million, while Life Sciences Products revenue increased 15.0% to $20.9 million.

  • Improved Gross Margin

    Gross margin improved slightly to 45.8% from 45.4% year-over-year.

  • Lower Loss from Discontinued Operations

    Loss from discontinued operations decreased significantly by 78.8% to $1.1 million.

  • Increased Cash Reserves

    Cash and cash equivalents totaled $272.9 million as of March 31, 2026, up from lower levels in the prior year.

  • Raising Annual Guidance

    Full-year revenue guidance has been raised to between $192 million and $196 million.

What to watch

  • Continued Operating Losses

    The company reported a net loss of $10.5 million, indicating ongoing financial challenges.

  • High SG&A Expenses

    SG&A expenses rose 26.1%, reflecting increased operational costs without corresponding revenue growth.

  • Foreign Exchange Exposure

    With $29 million in foreign-denominated cash, a 20% adverse change could result in a loss of $5.8 million.

Management's outlook

Full-year revenue guidance raised reflecting stronger performance and growth visibility.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.